Manifold MarketsChiusoSenza KYCDati di risoluzione verificatiDiscretamente calibratoQuesto mercato si è risolto: No (72.9%)
Risolto: 13 ago 2026, 10:03
Risoluzione verificata dal provider
CoinRithm dispone di prove del provider sul vincitore e sul momento di regolamento di questo mercato.
Previsione della comunità attualeNo 72.9%
Previsori
4
Tipo di domanda
binary
Metodologia
Play-money forecasting platform
Tipo di fonte
Previsione
Dati di mercato
Aggiornato 7 giorni fa
Obsoleto4 giu 24, 2:5813 ago 26, 10:03
Trend
72.9%
27.1%
Regole
https://www.jnj.com/media-center/press-releases/janssen-announces-late-breaking-data-from-two-gene-therapy-programs-at-the-american-academy-of-ophthalmology-2022-annual-meeting
- JNJ-81201887 (JNJ-1887), formerly referred to as AAVCAGsCD59, is an investigational gene therapy for the treatment of people with geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD).
- JNJ-1887 is designed to increase the expression of a soluble form of CD59 (sCD59) intended to protect retinal cells to slow and prevent disease progression.
- I expect to resolve this based on whether it passes Phase III trials but am willing to hear arguments otherwise.
- I also plan to extend the close date until it becomes clear one way or the other.
- If the pharma company working on this treatment completely abandons it before a Phase III result, I'll probably resolve NO.
